What are the terms of payment?

The accepted terms of payment are LC (Letter of Credit) and T/T (Telegraphic Transfer).

What is the average lead time for orders?

The peak season lead time is one month.

Is the production GMP approved?

Yes, the company has GMP approval by the SFDA of China for its manufacturing lines.

Irrigation Solution Surgery Use Large Volume

Name: Irrigation Solution Surgery Use Large Volume
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 875413795

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.20-1.00

10,000 Pieces

Sample price:US$0.00/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Model NO.

500ml 1000ml 2000ml 3000ml

Suitable for

Elderly, Children, Adult

State

Infusion

Shape

Injection

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

H13023203

Production Line

GMP Approved

Transport Package

2 Bags/Carton

Specification

500ml 1000ml 2000ml 3000ml

Trademark

SHIMEN

Origin

China

Key features

Large Volume IV Solution: 3000ml sterile Sodium Chloride 0.9% injection for internal medicine use.

High Production Capacity: Yearly output exceeds 1200 million bottles, including 40 million soft plastic bottles.

GMP Approved Manufacturing: Produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd. with SFDA GMP approval.

Global Market Reach: Products exported to South America, Africa, Asia, Oceania, and the Middle East.

Established Manufacturer: Company established in 1948 with over 3000 employees and USD 58 million capital.

Flexible Packaging Options: Available in 500ml, 250ml, 100ml, and 3000ml plastic bottles.

Industry Leading Quality: Leading position in quality, variety, and yearly output in China's infusion field.

Diverse Product Range: Manufacturer of 7 series medicines including infusions, capsules, and tablets.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤11.59hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.